| 000 | 01421 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250516122946.0 | ||
| 264 | 0 | _c20131111 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a1533-4023 | ||
| 024 | 7 |
_a10.1097/FJC.0b013e31827e0fa9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJenkins, Amanda | |
| 245 | 0 | 0 |
_aPharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. _h[electronic resource] |
| 260 |
_bJournal of cardiovascular pharmacology _cApr 2013 |
||
| 300 |
_a272-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 |
_aEpoprostenol _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRenal Dialysis |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aWang-Smith, Laurene | |
| 700 | 1 | _aMarbury, Thomas | |
| 700 | 1 | _aLaliberte, Kevin | |
| 773 | 0 |
_tJournal of cardiovascular pharmacology _gvol. 61 _gno. 4 _gp. 272-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/FJC.0b013e31827e0fa9 _zAvailable from publisher's website |
| 999 |
_c22297919 _d22297919 |
||